BrainStorm Cell Therapeutics appoints COO
Dr. Kern is an influential leader, consensus builder, and strategic advisor with expertise translating science into global solutions for patient care.
Dr. Kern was most recently Senior Vice President and Head of Worldwide Medical at Biogen.
From 2011 to 2014, Dr. Kern was Vice President and Head of Neuroscience Medical Unit at Novartis, where he developed and directed strategy, budget, and advanced medical-commercial governance model for neuroscience.
From 2006 to 2011, Dr. Kern was Global Medical Director of Personalized Genetic Health at Genzyme Corporation (now Sanofi Genzyme) where he championed global medical affairs and medical and scientific activities for Fabry disease life cycle management.
From 2003 to 2006, Dr. Kern was University Neurology Program Director at the University of Toronto.
Previously, he was a Neurologist Consultant at Mount Sinai Hospital, where he played a central role in identifying and publishing the first scientific description of central nervous system complications from the West Nile Virus epidemic in 2003.
From 1988 to 2001, Dr. Kern was Director, EMG, EEG, and Evoked Potential Laboratory at The Credit Valley Hospital, where he served on the Medicine Executive Committee and facilitated principal-investigator clinical trials for headache, epilepsy, and stroke.
Dr. Kern studied in the undergraduate Neurophysiology program at McGill University, received a Doctor of Medicine from Queen's University, completed post-graduate studies in neurology and neurophysiology at McGill University and a Master of Health Sciences (MHSc in Health Administration) from the University of Toronto. ■
LATEST MOVES FROM New York
- Wecast Network appoints Simon Wang as CFO
- Sequential Brands Group appoints Karen Murray as CEO
- Viacom appoints Kern Schireson as executive vice president
- S&P Global appoints Marco Alverà to board
- AIG CEO Peter D. Hancock to resign
More inside POST